The Prevalence of Cirrhosis in Patients with Hepatitis C Is Growing
February 29, 2016
Low participation raises concern for cancer clinical trials
February 29, 2016
Show all

Targeting Enzyme Slows Progression of Multiple Sclerosis

A new therapy involving an enzyme could reduce brain inflammation in multiple sclerosis.

A novel therapeutic approach to multiple sclerosis (MS) patients may be effective in reducing brain inflammation, according to findings published in the Journal of Neuroinflammation. Researchers from the University of Alberta Faculty of Medicine & Dentistry in Canada observed human fetal neurons and lymphocytes in 10- to 12 week old female mice in order evaluate the effect of the serine protease granzyme B (GrB) inhibition in mice models of MS.

Previously, the researchers demonstrated that GrB was a mediator of axonal injury and neuronal death, backed by other studies that suggest inflammatory cells influence the pathogenesis of MS likely through the use of GrB. Typical treatments for MS act on the immune system to reduce brain inflammation, the researchers explained in a press release, but negatively affect the immune system to the point that patients have to counteract significant side effects. GrB was targeted in this study as a source of brain inflammation that did not significantly suppress the immune system response in mice.

Read Full Article: Targeting Enzyme Slows Progression of Multiple Sclerosis


The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.